

# **Esophageal Cancer - Pipeline Review, H2 2020**

https://marketpublishers.com/r/EF536FD5BCFEN.html

Date: September 2020

Pages: 1584

Price: US\$ 2,000.00 (Single User License)

ID: EF536FD5BCFEN

## **Abstracts**

Esophageal Cancer - Pipeline Review, H2 2020

## **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H2 2020, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

## REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 77, 91, 7, 29, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 4 and 3



molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

#### Note:

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

### SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline



projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)

### **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## **Contents**

Introduction

Esophageal Cancer - Overview

Esophageal Cancer - Therapeutics Development

Esophageal Cancer - Therapeutics Assessment

Esophageal Cancer - Companies Involved in Therapeutics Development

Esophageal Cancer - Drug Profiles

Esophageal Cancer - Dormant Projects

Esophageal Cancer - Discontinued Products

Esophageal Cancer - Product Development Milestones

**Appendix** 



## **List Of Tables**

### LIST OF TABLES

Number of Products under Development for Esophageal Cancer, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Esophageal Cancer - Pipeline by AbbVie Inc, H2 2020

Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2020

Esophageal Cancer - Pipeline by ADC Therapeutics SA, H2 2020

Esophageal Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2020

Esophageal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2020

Esophageal Cancer - Pipeline by Affimed GmbH, H2 2020

Esophageal Cancer - Pipeline by AIMM Therapeutics BV, H2 2020

Esophageal Cancer - Pipeline by Akeso Inc, H2 2020

Esophageal Cancer - Pipeline by Alphamab Oncology, H2 2020

Esophageal Cancer - Pipeline by Ambrx Inc, H2 2020

Esophageal Cancer - Pipeline by amcure GmbH, H2 2020

Esophageal Cancer - Dormant Projects, H2 2020

Esophageal Cancer - Discontinued Products, H2 2020



## **List Of Figures**

#### LIST OF FIGURES

Number of Products under Development for Esophageal Cancer, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

#### **COMPANIES MENTIONED**

AbbVie Inc

Adaptimmune Therapeutics Plc

**ADC Therapeutics SA** 

Advanced Accelerator Applications SA

Advenchen Laboratories LLC

Affimed GmbH

AIMM Therapeutics BV

Akeso Inc

Alphamab Oncology

Ambrx Inc

amcure GmbH

AMI Onco Theranostics LLC

Anhui Anke Biotechnology (Group) Co Ltd

Anhui Kedgene Biotechnology Co Ltd

Apexigen Inc

Apollomics Inc

Aprea Therapeutics Inc

Arog Pharmaceuticals Inc

Ascenta Therapeutics Inc

Ascentage Pharma Group International

Astellas Pharma Inc.



AstraZeneca Plc

**AVEO Pharmaceuticals Inc** 

Bayer AG

BeiGene Ltd

Bicycle Therapeutics Plc

BioMed Valley Discoveries Inc

Biostage Inc

BioStar Pharmaceuticals Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Cantargia AB

Celldex Therapeutics Inc

Chengdu Jinrui Foundation Biotechnology Co Ltd

Chi Cheung (Shanghai) Biomedical Co Ltd

Chugai Pharmaceutical Co Ltd

Coherent Biopharma

Cotinga Pharmaceuticals Inc

CStone Pharmaceuticals Co Ltd

Curegenix Inc

Cyclacel Pharmaceuticals Inc

Cytlimic Inc

CytomX Therapeutics Inc

DAE HWA Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Delta-Fly Pharma Inc

Dragonboat Biopharmaceutical (Shanghai)Co Ltd

**Dragonfly Therapeutics Inc** 

Eisai Co Ltd

Eli Lilly and Co

Exelixis Inc

F. Hoffmann-La Roche Ltd

Genentech USA Inc

Genmab AS

GlaxoSmithKline Plc

GLG Pharma SA

GlycoNex Inc

Glycotope GmbH

Gossamer Bio Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd



Guangzhou Anjie Biomedical Technology Co Ltd

Guangzhou Saliai Stemcell Science and Technology Co Ltd

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

HEC Pharm Co Ltd

Hualan Biological Engineering Inc

Hutchison MediPharma Ltd

Idera Pharmaceuticals Inc

ImmuneSensor Therapeutics Inc

Immunocore Ltd

Immunomedics Inc

ImmunoRestoration Inc.

Immvira Co Ltd

Incyte Corp

Innovent Biologics Inc

Inovio Pharmaceuticals Inc

Ipsen SA

Jacobio Pharmaceuticals Co Ltd

JenKem Technology Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Simcere Pharmaceutical Co Ltd

Johnson & Johnson

Kitov Pharma Ltd

Kymab Ltd

Leap Therapeutics Inc

**LEXEO Therapeutics LLC** 

LIfT BioSciences Ltd

Lycera Corp

MaxiVAX SA

Medical Guidance Systems LLC

Merck & Co Inc

Merck KGaA

Mereo Biopharma Group Plc

Moderna Inc

Modra Pharmaceuticals BV

Molecular Templates Inc

Myeloid Therapeutics Inc

New B Innovation Ltd

NGM Biopharmaceuticals Inc



Novartis AG

Novita Pharmaceuticals Inc

**OBI** Pharma Inc

**Omeros Corp** 

Omnitura Therapeutics Inc

Oncolys BioPharma Inc

Onconova Therapeutics Inc

Ono Pharmaceutical Co Ltd

PDS Biotechnology Corp

Peptron Inc

Pfizer Inc

Pieris Pharmaceuticals Inc

Precigen Inc

Puma Biotechnology Inc

Quadriga BioSciences Inc

Rafael Pharmaceuticals Inc

Rakuten Medical Inc

RAPT Therapeutics Inc

RaQualia Pharma Inc

Replimune Ltd

**Revolution Medicines Inc** 

Rhizen Pharmaceuticals SA

Scancell Holdings Plc

Seattle Genetics Inc

Seven and Eight Biopharmaceuticals Corp

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Shanghai Haihe Biopharma Co Ltd

Shanghai Henlius Biotech Inc

Shanghai Junshi Bioscience Co Ltd

Shanghai Keqi Pharmaceutical Technology Co Ltd

Shanghai Miracogen Inc

Shenyang Dongxing Pharmaceutical Co Ltd

Shenzhen BinDeBio Ltd

Shenzhen Hornetcorn Bio-technology Company Ltd

Shenzhen NeoCura Biotechnology Corp

Shionogi & Co Ltd

Sino Biopharmaceutical Ltd

Sinocelltech Ltd

Smerud Medical Research International AS



Soricimed Biopharma Inc

Sorrento Therapeutics Inc

Starpharma Holdings Ltd

Steba Biotech SA

Stemirna Therapeutics Inc

Supratek Pharma Inc

Sutro Biopharma Inc

Suzhou Sinovent Pharmaceuticals Co Ltd

Suzhou Stainwei Biotech Inc

TAE Life Sciences LLC

Taiho Oncology Inc

Takara Bio Inc

Telix Pharmaceuticals Ltd

Tessa Therapeutics Ltd

Themis Bioscience GmbH

TOT Biopharm Co Ltd

Transgene Biotek Ltd

Transgene SA

Turnstone Biologics Inc

Tyg Oncology Ltd

Viral Gene Inc

VM Discovery Inc

Xiangxue Life Sciences

XuanZhu Pharma Co Ltd

Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd

Zymeworks Inc



## I would like to order

Product name: Esophageal Cancer - Pipeline Review, H2 2020

Product link: <a href="https://marketpublishers.com/r/EF536FD5BCFEN.html">https://marketpublishers.com/r/EF536FD5BCFEN.html</a>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

## **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/EF536FD5BCFEN.html">https://marketpublishers.com/r/EF536FD5BCFEN.html</a>